

BIOVALLEY COMPANIES DAY 2023

May 09, 2023 Freiburg

Company Profiles

Main Sponsors:













Dear BioValley members, partners and friends,

I am honored to welcome you all to the BioValley Companies Day 2023. This event brings together some of the brightest minds and innovative companies from our region's life sciences industry, creating a unique opportunity for collaboration and sharing of knowledge.

When the BioValley associations were founded around the year 2000, it was already clear that the border triangle of France, Germany and Switzerland was an economically very strong region. Life Sciences play a very important role in the French region Alsace with Strasbourg and Mulhouse, in Germany from Karlsruhe via Freiburg to Lörrach as well as in the metropolitan areas of Basel and Zurich on the Swiss side. Not only are there headquarters and production sites of very large companies, but also solid medium-sized companies and new start-up companies in the pharmaceutical, biotechnology and medical technology sectors. In addition to all the companies with their economic power, the tri-national region's institutes, universities and university clinics as well as business development agencies have an excellent reputation.

Many years ago BioValley Deutschland e.V. came up with the special format of the BioValley Companies Day. It allows as many players as possible to connect in the shortest possible time: participants present themselves in concise, short presentations throughout the day with networking opportunities during the breaks. This format has repeatedly been highly praised by its participants. All companies are given equal attention, regardless of whether they are large or small, long-established or start-ups. As always this networking event is expressly designed for companies from the entire tri-national area of the BioValley.

Despite the popularity of virtual meetings during the pandemic our experience has been that nothing beats a face-to-face meeting. This is exactly what we would like to revive. Do not miss the opportunity of meeting many of the most interesting business actors in the region. In addition to sharing experiences, the explicit goal of this event is the initiation of joint business.

I would like to thank all of our speakers, sponsors, and partners for their contribution to this year's Company Day. Your participation is essential to the success of this event, and I am looking forward to many engaging discussions and opportunities for collaboration.

Sincerely,

Dr. Raphael Vogler President Biovalley Germany CEO ChemCon GmbH

4HF Biotec GmbH

4HF's goal is to transform conventional cytotoxic chemotherapy into cancertargeted therapy.

Worldwide >8 million patients with advanced cancer need chemotherapy every year (WHO-2022). However, conventional chemotherapy has dose-limiting side effects due to lack of selectivity for tumor as compared to normal cells. For developing cancer-targeted therapy, we attach a cytotoxic effector to a cancer-targeting component which specifically directs the effector to cancer cells.

In a first step, we have established the Cancer DataMiner, a platform integrating molecular data of >1.850 tumor models, >10.000 patient tumors and >12.000 normal tissues. The DataMiner allowed us to identify cancer-associated proteins, our drug targets. More than 100 proteins fulfil our strict criteria.

In a second step, we use in silico chemistry and AI to discover small molecule ligands of our targets which we optimize chemically. Finally, we fuse the ligands with cytotoxic effectors in one molecule. The conjugate formats we favor include small molecule drug conjugates (SMDCs) and radioligands (in an Invest BW-funded cooperation).

We profile our conjugates preclinically to identify clinical candidates. Beyond our drug discovery efforts, we offer some of our bioinformatics capabilities as fee for service.

Actome GmbH

Actome is a biotech start-up, founded in 2017, developing cutting edge technology in the field of proteomics and interactomics. We are located in Freiburg im Breisgau, a thriving pharmaceutical and biotechnological hub in Europe. Our business is based on a novel molecular biological analysis technology termed "Protein Interaction Coupling (PICO)" invented by one of the founders Dr. Csaba Jeney.

We support life science research and medical innovations by enabling the quantification of proteins, protein interactions, and post-translational modifications in biological samples with hitherto unseen sensitivity and specificity. The easy-to-use PICO assay kits combine the advantages of antibody-based immunoassays with the robustness and sensitivity of digital PCR.

Innovative personalized health care requires highly sensitive analysis of proteins and protein interactions as biomarkers in the smallest amounts of biological samples. Exploring complex cellular interaction pathways and drug target interactions are further eminent applications in research and development. PICO solves the problem of highly sensitive, specific, and robust measurement of proteins and protein interactions in their native environment. Only minute amounts of biological samples are required (e.g. single cells) and a large number of targets can be measured simultaneously.



Contact Person: Anja Honeker

Adress: Am Flughafen 14 79108 Freiburg, Germany

Phone/E-Mail: + 49 (0)761 7088 93-0 anja.honeker@4hf.eu

www.4hfbiotec.com



Contact Person: Philipp Lübbert

Adress: Georges-Köhler-Allee 103 79110 Freiburg, Germany

Phone/E-Mail: +49 (0)761 216 305 07 philipp.luebbert@actome.de

www.actome.de



Contact Person: Dr. Aleksandra Konovalova

Adress: Hammerstrasse 49 4410 Liestal, Switzerland

Phone/E-Mail: +41 61 90 64 000 akonovalova@anapath.ch

www.anapath.ch



Contact Person: Hilde Huber

Adress: Munzingerstr. 5a 79111 Freiburg, Germany

Phone/E-Mail: +49 (0)761 479 4000 info@akp-freiburg.de

www.akp-freiburg.com

AnaPath Services GmbH

AnaPath Services (APS) based in Switzerland and AnaPath Research (APR) based in Spain are reputable CROs for Pharma, Biotech, (Agro)Chemical & MD companies. APR provides general toxicological studies, PK/PD, reproductive & developmental toxicology, veterinary products testing, bioanalytical services. APS is specialized in toxicologic pathology, histotechnology, necropsy, endocrine disruptor evaluation IHC, TCR, TEM, SEM, fetal & molecular pathology, material science.

Arbeitskreis Klinische Prüfungen (AKP) GmbH

AKP is an independent contract research organization (CRO) with over 27 years of experience in providing clinical research services (clinical trials phases I-IV, clinical investigations, performance evaluation studies, Post Market Clinical Follow-up (PMCF), non-interventional studies (NIS)) to the pharmaceutical and biotechnical industry, medical device and in-vitro diagnostics (IVD) manufacturers and universities.

As an owner-managed CRO, AKP offers their clients both professional advice and efficient project execution in a variety of therapeutic areas.

Portfolio of services:

- Comprehensive Counsel & Planning of Clinical Trials
- Study-/Project Management (national und international)
- Regulatory Affairs
- Quality Assurance
- (e)CRF Design
- Data Management
- Statistics

Arcondis

Arcondis is a global consulting company with an exclusive focus on the healthcare and life science industries, with their particularly demanding requirements on quality and regulatory affairs.

We have been addressing challenges and solving problems for our clients in the areas of compliance, business processes, information technology, and digital transformation since 2001.

We create value through cross-functional, sophisticated delivery methodologies and intelligent implementation. Our clients love to work with us because of our unique skillsets, our pragmatic approach, and our will to win.

We make healthcare better.



Contact Person: Florian Unverzagt

Adress: Hegenheimermattweg 167b 4123 Allschwil, Switzerland

Phone/E-Mail: +41 79 693 17 04 florian.unverzagt@arcondis.com

www.arcondis.com

Asterivir AG

Asterivir is developing a broad-spectrum antiviral platform invented at the Swiss Federal Institute of Technology in Lausanne (EPFL).

Contrary to existing antivirals that interfere with viral replication within host cells, Asterivir's medicines employ a unique extra-cellular mechanism of action (MOA) that irreversibly renders virus particles non-infective. The technology has proven is effectiveness in-vitro against a wide variety of viruses, and in-vivo against Influenza, RSV, HSV-2 and SARS-CoV-2. In headto-head benchmarks, Asterivir's molecule against influenza has shown clear superiority over Tamiflu in terms of therapeutic window, while showing no signs of toxicity at up to 20x therapeutic doses.

Asterivir is focussed on preparing its lead molecule against influenza for formal pre-clinical studies and is open to partnerships to advance programs using its platform technology to address other viral diseases.



Contact Person: Oscar Bust

Adress: Rue Louis de Savoie 27 1110 Morges, Switzerland

Phone/E-Mail: +41 79 353 66 60 oscar@asterivir.com

www.asterivir.com



Contact Person: Dr. Hubert S. Bernauer

Adress: Weberstr. 40 79249 Merzhausen, Germany

Phone/E-Mail: +49 179 66 07 141 info@atq-biosynthetics.de

www.atg-biologics.com



Contact Person: Kerstin Maike Schmitz, Ph.D.

Adress:

Openzone Via Meucci 3 20091 Bresso (Milan), Italy

Phone/E-Mail: Office: +39 02 21 05 665 Mobile: +39 34 42 13 38 04 kerstin.schmitz.ks@axxam.com

www.axxam.com

ATG:biosynthetics GmbH

ATG:biosynthetics provides **A**=advanced, **T**=technical, **G**=genetics and is your partner for all issues regarding molecular biodesign and realization of applications in synthetic biology.

Our deep experience in bioinformatics in this fields is based on evolutionary comparative X'omics. Here we are focussed on extracting essential objective molecular information very important for modulating levels of diverse gene products and metabolic biomolecules used for realizing the planning of projects and creating applications. Proven analytical data are subsequently used for rational DNA sequence calculations directed to genes and regulators. This is intended either for introducing translationally silent mutations for the improvement of expression in respect to co-translational requirements or non-silent mutations directed to change the amino acid composition of target proteins like enzymes for phenotypical functional improvements.

Our approach opens a wide scope into all fields of life sciences. In terms of applications which can be anticipated are protein engineering e.g. improvement of properties of individual enzyme action in industrial processes as well as building higher order genetic structures like artificial biochemical pathways e.g. for new antibiotics.

Axxam SpA

Axxam is a leading provider of integrated discovery services across Life Sciences industry.

Within the drug discovery disciplines, we support pharma, biotech companies, start-ups, patient foundations as well as academic groups in their journey from hit identification to lead generation, regardless of the therapeutic area and target class.

Our services include assay development, high-throughput screening of both the Axxam high quality compound collections (synthetic and natural) or those provided by our clients, hit validation, compound management. The same science-driven approach is also applied to identify new bioactive compounds for crop protection, animal health, food, beverage, pet food, cosmetic and perfume industries.

BioCopy GmbH

BioCopy is a multinational company headquartered in Switzerland with a state-of-the-art R&D facility in Emmendingen, Germany.

BioCopy focuses on drug discovery for immune-oncological therapeutics, in particular T-cell engagers. The extensive patent portfolio focuses on high-throughput analyses with a broad range of applications, currently centered on the characterization of immune responses for drug discovery. With the BioCopy platform technology, TCR(m) interactions with thousands of peptide-HLA complexes can be screened label-free and in high-throughput.

BioCopy builds on many years of extensive experience in microarray customization, high-throughput binding kinetics and bioinformatics. We characterize and validate immune responses of TCR(m)-based immuno-oncology drug candidates in our own drug development – and as a service for partners during pre-clinical phases, in drug discovery as well as in hit and lead screening.



Contact Person: Dr. Claudia Duppé, Strategic Marketing & Communications

Adress: Elzstraße 27 79312 Emmendingen,Germany

Phone/E-Mail: +49 (0)151 62 98 69 30 claudia.duppe@biocopy.de

www.biocopy.com

BIOPRO Baden-Württemberg GmbH

The state agency BIOPRO Baden-Württemberg is your contact partner for the Healthcare Industry (Medtech – Pharma – Biotech) in Baden-Württemberg. With some 1.100 companies and research institutions, BIOPRO aims to team players across industry boundaries, bring industry and science together, provide information on regulatory requirements and generate new impulses for Baden-Württemberg.



Contact Person: Dr. Tim Höschele

Adress: Alexanderstraße 5 70184 Stuttgart, Germany

Phone/E-Mail: hoeschele@bio-pro.de

www.bio-pro.de



Contact Person: Agnès Legoll, External Relations Director

Adress: 2, rue Marie Hamm Bâtiment eXplora 67000 Strasbourg, France

Phone/E-Mail: +33 68 02 65 202 aqnes.legoll@biovalley-france.com

www.biovalley-france.com



The Microplate Reader Company

Contact Person: Dr. Tobias Pusterla

Adress:

Allmendgrün 8 77799 Ortenberg, Germany

Phone/E-Mail: +49 (0)781 96 96 80 Tobias.Pusterla@bmglabtech.com

www.bmglabtech.com

BIOVALLEY FRANCE

Based in Eastern France, BioValley France competitiveness cluster brings to the health community its unique expertise and personalized support around 4 areas: Drugs and Innovative Therapies, Medical Technologies, E-health and Diagnostics.

For more than eighteen years, BioValley France has built a powerful community in order to deploy a strong network mixing academics and industrials in the health sector: more than 280 members have today decided to join the Cluster in order to share, exchange and develop tomorrow's innovation in the best optimal conditions.

BioValley France offers various services to its members covering: Business competitiveness, Innovative and collaborative Projects, International relations, Visibility and Influence.

BMG LABTECH GmbH

BMG LABTECH is a leading global developer and manufacturer of innovative, high-quality, and reliable microplate reader instrumentation.

BMG LABTECH has been committed to producing microplate readers for more than thirty years and is the only independent company solely focused on these instruments. By focusing on the needs of the scientific community, the company's microplate readers have earned the company the reputation of being a technology leader in the field. BMG LABTECH's dedicated and multi-mode microplate readers are used in many different research areas and offer solutions for almost any application and budget.

All BMG LABTECH microplate readers are conceived, developed, assembled, and tested entirely at our headquarters in Ortenberg, Germany. Since its establishment, BMG LABTECH has expanded to offer a worldwide sales and support network with offices in the USA, UK, Australia, Japan and France. Moreover, the company is represented in more than 50 countries by selected distributors.

CapCo Bio GmbH

CapCo Bio GmbH will revolutionize the transport of biomolecules into eukaryotic cells through its unique, newly developed technology. This breakthrough technology will open up completely new avenues for research into the molecular bases, treatment and prevention of many diseases.

The products will initially be developed for the research use only (RUO) market, with a mid- to long-term view towards launching products for gene therapy and targeted active pharmaceutical drug delivery (API)in humans.

Long-term growth will be ensured by continuous portfolio expansion and by strategic, productive partnerships.

The IP consists of biodegradable submicron and nano capsules that can be loaded with nucleic acids or other cargo. These capsules utilize the cell's natural uptake pathways to transport their cargo into the cells owing to their high degree of similarity to cellular structures.

This method of cellular transport results in a higher efficiency than existing methods, while ensuring maximum biocompatibility and minimal toxicity. The product also promises high levels of customer acceptance thanks to its simple handling.

СарСовю

Contact Person: Dr. Arnold Martin

Adress: Egonstraße 51-53 79106 Freiburg, Germany

Phone/E-Mail +49 (0) 761 88 84 220 arnold.martin@capcobio.de

www.capcobio.de

Sartorius CellGenix GmbH

Sartorius CellGenix is a leading global supplier of high quality raw materials for the expanding cell and gene therapy and regenerative medicine space. We develop, manufacture and market human cytokines and growth factors along with GMP serum-free media. To allow for a seamless transition from preclinical development to the clinical stage we offer our human cytokines and growth factors in preclinical and GMP quality. Our products are used by academia and industry partners in clinical trials and commercial manufacturing throughout the world.

With 25+ years of experience we are experts in the GMP manufacturing of raw materials for the cell and gene therapy space. As a former ATMP developer and manufacturer we gained in-depth cell culture knowledge and superior regulatory expertise. With this unique background we understand the high requirements our customers face during product development and the regulatory approval process. By offering expert technical and regulatory support we can help simplify raw material qualification and validation efforts.

Sartorius CellGenix operates a state-of-the-art GMP facility for production of recombinant proteins and cell processing in Freiburg, Germany.



Adress: Am Flughafen 16 79108 Freiburg, Germany

Phone/E-Mail: +49 (0)761 88 889-0 info@cellgenix.com

www.cellgenix.com



Contact Person: Dr. Michael Woydt, Head of Marketing

Adress: Engesserstraße 4b 79108 Freiburg, Germany

Phone/E-Mail: +49 (0)761 5597-0 info@chemcon.com

www.chemcon.com



Contact Person: Dr. Katrin Driller

Adress: Badenweilerstraße 4 79115 Freiburg, Germany

Phone/E-Mail: +49 (0)761 47 813-0 k.driller@crc.de

www.crc.de

ChemCon GmbH

ChemCon is a chemical service provider to the pharmaceutical and biotechnology industry. We are a contract development and manufacturing partner for active pharmaceutical ingredients (APIs) and fine chemicals, specialized in transferring R&D projects into fully cGMP-compliant manufacturing processes.

Customers worldwide use our services to source APIs for clinical trials and/ or commercial applications (i.e. orphan diseases), excipients, reference standards, and all kinds of other high-quality specialty chemicals. Our FDAinspected facilities are optimized for the production of small to medium quantities. With multidisciplinary expertise we can meet your individual demands for organic small-molecule APIs, inorganic salts and complexes including trace elements, polymers, and highly potent or controlled substances – all in full cGMP quality up to injection grade. With a history of more than 25 years, ChemCon has an outstanding inspection history by both: the FDA and European health authorities.

If you are looking for ICH-compliant quality control, method development and validation, impurity determination, release analysis, or reference standard qualification ChemCon's analytics team takes care of your inquiries. Beyond our CDMO business, ChemCon is offering selected commercial APIs and GMP salts.

CRC Clean Room Consulting GmbH

HIGH-TECH SOLUTIONS FROM HI-TEC ENGINEERING

CRC is an internationally active planning office for the high-tech and life science industry and research. We specialise in laboratories, clean rooms, research buildings and highly complex manufacturing buildings.

We have been solving highly complex tasks for our customers and partners from industry and research for over 40 years. We plan all technical trades to supply the production technology, the processes and the production environment. We see ourselves as an active partner for clients, users, project developers and architects.

Our services: everything from one source

Cleanroom planning, laboratory planning, building services planning, media planning - we provide the entire planning spectrum through our own engineers, architects, scientists, technicians and system planners. This reduces interfaces and optimises processes.

Our focus: high-tech and life science

Our clients are leaders in their field. They produce, research and develop and are active in the high-tech industry and in the life science sector, for example in electronics, semiconductors, optics, battery cells, pharmaceuticals and medical technology.

Drees & Sommer SE

Drees & Sommer is your innovative partner for Consulting, Planning, Construction and Operation.

As a leading European consulting, planning and project management company, Drees & Sommer has been supporting private and public sector clients and investors for over 50 years in all matters relating to real estate and infrastructure – both analog and digital.

Through pioneering consulting, the company offers solutions that deliver successful buildings, high-yield portfolios, efficient infrastructure, and livable cities. Working in interdisciplinary teams, the company's 4,500-plus employees at 51 regional offices worldwide support clients from a wide range of industries.

The Partner-managed company delivers all services on the understanding that economy and ecology must be combined. At Drees & Sommer, this holistic approach is called "the blue way".

DREES & SOMMER

Contact Person: Stefan Kattendick

Adress: Salzstraße 15 79098 Freiburg, Germany

Phone/E-Mail: +49 (0)761 88 17 90 – 210 stefan.kattendick@dreso.com

www.dreso.com

eleva GmbH

Based in Freiburg, Germany, Eleva develops novel biological therapies with its pharmaceutical partners.

The privately-held company leverages its unique moss-based production platform to produce supreme biologics like antibodies, replacement enzymes, or fusion toxins. Eleva has successfully developed drug candidates into clinical phases.



Contact Person: Dr. Andreas Schaaf

Adress: Hans-Bunte-Straße 19 79108 Freiburg, Germany

E-Mail: bd@elevabiologics.com

www.elevabiologics.com



Contact Person: Dr. Nicholas Krohn

Adress: Georges-Köhler Allee 302 79110 Freiburg, Germany

Phone/E-Mail: +49 (0)151 150 85 261 Nicholas.Krohn@endress.com

www.ehbs.endress.com



Contact Person: Bertrand Verwee

Adress: Engelgasse 43 4052 Basel, Switzerland

Phone/E-Mail: +41 79 136 80 44

bertrand.verwee@excensis.com

www.excensis.com

Endress+Hauser BioSense GmbH

Endress+Hauser BioSense GmbH is a joint venture of Endress+Hauser and Hahn-Schickard that develops and provides innovative PCR-based detection systems.

The systems employ advanced microfluidic technologies, allowing on-site analyses without requiring specialized laboratory infrastructure. These detection systems are adaptable to detect pathogens, spoilage bacteria, and microbial contamination in various industries to assure product safety, hygiene, compliance, and sustainability.

Endress+Hauser BioSense combines advanced microfluidic automation with innovative sample preparation techniques to offer streamlined workflows without specialized personnel.

Excensis GmbH

If you are developing medicines, medical devices or health apps, be ahead of the curve (and your competitors) by integrating patient-centricity into your developments now. Patient-focused developments have become a prerequisite for success, whether at development, regulatory or market access stage, or for competitive commercialisation purposes.

Excensis is a consultancy providing life sciences companies with strategic advice and hands-on execution of patient-centric projects and solutions. The focus is on accelerating the process of innovation, increasing probability of success in commercialisation, and serving patients by eliminating a recognised key unmet need.

Excensis connects companies with patient organisations in a partnership model based on mutual trust, co-creation, and benefit to all parties, building company reputation and value by strongly anchoring your company with the future key stakeholders in healthcare: patient organisations.

Excensis is well net-worked, with the possibility to quickly mobilise support from a wide network of highly experienced professionals in life sciences covering the entire lifecycle, to provide tailor-made solutions for your patient-centric endeavours.

Epinar Pharma

Epinar Pharma is a seed-stage biotech company founded in June 2022 to develop innovative therapies for sleep disorders, particularly hypersomnias and narcolepsy with cataplexy (NC). NC affects 0.05% of the general population and is treated symptomatically with medications that currently generate \$2.5B in sales annually.

Contrary to existing therapies, which seek to alleviate NC symptoms, Epinar's medicines will address the underlying cause of the disease. Thanks to a discovery first made by Prof. Mehdi Tafti and myself at the University of Lausanne (UNIL), it is now known that the gene responsible for sleepregulation (the hypocretin (HCRT) gene) is not absent in NC patients as previously thought, but rather has been epigenetically silenced through a process known as methylation.

Epinar Pharma plans to develop medications to reverse this process, thanks to an exclusive license to the UNIL patents covering this process, and so produce curative therapies, or at least evidence-based treatments, for NC.



Contact Person: Ali Seifinejad

Adress: 27 rue Louis-de-Savoie 1110 Morges, Switzerland

Phone/E-Mail: ali.seifinejad@mail.ch

IKA-Werke GmbH & Co. KG

IKA develops and produces state-of-the-art solutions for laboratories and the process industry. To bring even more success to the work of our customers and users, we combine the latest technology with innovative design and think far into the future. Our products are ready for integration into the digital laboratory.

We are a responsible family business and at the same time a global player. We've been around for over 111 years. Every day, our more than 900 employees contribute to expanding our leading global market position in laboratory, analytical, and process technology. At our headquarters in Staufen, Germany, we develop our products and technologies in cooperation with application experts from science and industry, and from there we sell them to more than 160 countries.

For excellent local service, IKA also operates its own subsidiaries in the USA, China, India, Malaysia, Brazil, Japan, Korea, Vietnam, United Kingdom, Poland, Thailand and Turkey.



Contact Person: Navid Ahmad

Adress: Janke & Kunkel Straße 10 79219 Staufen, Germany

Phone/E-Mail: +49 (0)7633 831-307 navid.ahmad@ika.de

www.ika.com/de



Contact Person: Dr. Uwe Schulte

Adress: Schlossstraße 14 79232 March-Buchheim, Germany

Phone/E-Mail: +49 (0)761 20 35 127 u.schulte@logopharm.com

www.logopharm.com



Contact Persons:

Céline Futterknecht, Brand Director Anne Klipfel, Marketing & Communications Manager

Adress: Messeplatz 4058 Basel, Switzerland

Phone/E-Mail: +41 58 206 23 70 celine.futterknecht@ilmac.ch +41 58 206 31 06 anne.klipfel@ilmac.ch

www.ilmac.ch

Logopharm GmbH

LOGOPHARM GmbH is a biotech company that provides specialized services in proteomic target, antibody and biomarker R&D.

The company located at Freiburg (Germany) was founded 2005 by a team of scientists and business experts. It combines proprietary developments, advanced instrumentation, scientific excellence and long-term experience in membrane protein analysis and molecular physiology to tackle even the most challenging targets, like ion channels, G-protein coupled receptors or other membrane receptors and transporters. Molecular characterization of these targets delivers relevant information for drug development, such as post-translational modifications, subunit compositions, interaction partners, changes in abundance or cellular localization, signaling pathways and (patho)physiological mechanisms.

Our specialized technology platforms include

- multi-epitope AP-MS and high-resolution complexome profiling approaches for targeted and comprehensive identification of native protein-protein interactions,
- micro-proteomic analysis of tissue samples with superior sensitivity,
- high-content profiling of antibodies,
- precise quantification of proteins by label-free mass spectrometry,

and are offered preferably on a fee-for-service basis.

MCH Messe Schweiz (Basel) AG/Ilmac

About ILMAC:

Basel fusion point of the pharmaceutical and chemical industry

ILMAC covers the entire Swiss market, and the Basel Exhibition Center is the perfect location for the Swiss pharmaceutical and chemical industry. As a user-oriented trade fair, the event is aimed at specialists from over 20 different branches of industry in the pharmaceutical, chemical, biotechnological, food, beverage, cosmetics and other sectors.

Despite the variety, ILMAC is extremely manageable and can be visited in one day.

ILMAC is diverse, manageable and local:

- Benefit from Basel's location, its proximity to the pharmaceutical and chemical industries
- Meeting place for the life science community
- Attractive programme with knowledge transfer & networking

More Information: www.ilmac.ch

ILMAC 2023

Starting: 26 September 2023 Ending: 28 September 2023 Where: Messe Basel | Hall 1.0

MOBIL+MED AG

Painless to go, with often just one application!

Current, notarial explanations of oath, prove it! It was demonstrated in a variety of events. People with pain are sustainably freed by them. This fact is then explained by you, instead of oath and the signature under this document is subsequently certified by a notary.

The Tesla coil was shrunk from a diameter of 3 meters to 30cm, with the same properties as in 1898 and transformed into the 21st century. The proof of effectiveness was already provided at that time and therefore our current knowledge is not new.

This development originally goes on Dr. Tesla + Dr. Lakhovsky back. Current, notarized explanations of oath, prove it! Medical laypersons can also use this technology safely.



Contact Person: M. Westphalen

Adress: Höhgasse 12 8598 Bottighofen, Switzerland

Phone/E-Mail: +49 (0)172 37 33 220

www.medplusmobil.ch

opto biolabs GmbH

Opto Biolabs, based in Freiburg, Germany, is a biotechnology company focused on the development and production of cutting-edge devices for optogenetic research. These devices enable precise illumination and control of optogenetic in-vitro systems.

Opto Biolabs has already launched 2 innovative products for the establishment of optogenetic flow cytometry and cell culture. Future products for more automated systems are in development.

Opto Biolabs' innovative solutions are designed to meet the complex demands of light-based research, helping scientists uncover novel insights into cellular mechanisms and drive therapeutic discovery for a range of diseases. Opto Biolabs sees the opportunity of a First-Mover advantage in the exciting, fast growing field of optogenetics.



Contact Person: Dr. Kathrin Brenker

Adress: Georges-Köhler-Allee 302 79110 Freiburg, Germany

Phone/E-Mail: +49 (0)176 85 90 1130 k.brenker@optobiolabs.com

www.optobiolabs.com

PharmaKorell

Contact Person:

Dr. Ulrich Korell, Managing Director

Adress:

Georges-Köhler-Str. 2 79539 Lörrach, Germany Schleißheimer Str. 373 80935 München, Germany

Phone/E-Mail:

+49 7621 949860 ulrich.korell@pharmakorell.com

www.pharmakorell.com



Contact Person: Dr. Sc. Bernard Ludwig

Adress: 8 Place de l'Hôpital 67000 Strasbourg, France

Phone/E-Mail: +33 (0)63 70 23 017 b.ludwig@preciphos.com

www.preciphos.com

PharmaKorell GmbH

GMP consulting plus certification: We do not just give good advice - we also take full responsibility! PharmaKorell GmbH is an independent service provider for GMP consulting and QP certification of API and drug product batches, based on its own EU Manufacturing and Import Authorization (MIA). Customers range from start-up to multinational companies; products range from Phase I IMPs to commercial products.

Additional services are: External QPs for MIA holders and Responsible Persons for WDL holders; GMP/GDP storage at 15...25°C, 2...8°C, -30...-15°C, -85...-75°C; site of physical importation; labelling of IMPs; sampling and primary packaging of APIs and drug products under clean room conditions (Grade A for particles, Grade D for microbiology); renting individual offices (ca. 25 m²) and providing virtual office services for pharmaceutical companies who need a business location in the EU.

PharmaKorell GmbH was founded in 2007 in Lörrach, Germany, and a small daughter company was founded in 2012 in Riehen, Switzerland. In 2020, PharmaKorell (Lörrach) moved to a brand-new building in Lörrach with excellent working conditions. In July 2022, PharmaKorell opened an office in Munich City.

The team consists of 27 permanent employees, most of them experienced pharmacists, chemists, or biologists, including 14 registered QPs. We are currently hiring more Consultants and Senior Consultants for further growth in Lörrach and Munich.

New cooperations and business opportunities are very welcome. Please contact us!

PRECIPHOS

Preciphos was founded in January 2018 in Strasbourg. We are developing technologies (a miniaturized on-chips immunoassay with fluorescence detection and a miniaturized imaging technology) in collaboration with the Swiss Federal Institute of Technology Zürich, the imaging Institute iCUBE Strasbourg and two Swiss University Hospitals in order to establish a medical diagnosis and prognosis within less than three hours at an affordable cost.

These analyses are performed in the medical department of hospitals by nurses or nurse-assistants under the supervision of physicians. Ultimately, the nurse or nurse-assistant will propose the medical diagnosis by using the integrated software associated to our technologies in an attempt to still improve the productivity of the medical staff. Our goal is to significantly decrease the healthcare costs while accelerating the implementation of the appropriate therapeutic strategy thus improving the patient life.

With our technologies, precision medicine is done close to the patient rather than in a medical laboratory. We are presently working on inflammation in infant where only minutes amounts of blood can be collected, the early large-scale diagnosis of cervical cancer, and cardiovascular diseases where we co-own the use of innovative biomarkers.

Reach Separations SAS

Reach Separations is a service company that specialises in chromatography for the analysis and purification of small molecules.

The latest HPLC and SFC technologies are used side by side for chiral and achiral separations to support our clients across the pharmaceutical, agrochemical, natural product, flavour & fragrance and fine chemical sectors.

We can perform purification on request or develop methods that can be transferred to the customer up to production scale.



Contact Person: Stéphane Dubant

Adress: 16 rue d'Ankara 67000 Strasbourg, France

Phone/E-Mail: +33 61 86 16 980 s.dubant@reachseparations.com

www.reachseparations.fr

Reinraum Tech AG

Reinraum Tech AG advises, plans and builds laboratories and cleanrooms. We accompany you from the initial idea through concept and realization to qualification and regular maintenance.

The ever increasing pressure to limit investment costs, rapid ROI, increase efficiency and rising regulatory requirements can best be met with small and flexible units.

Cleanroom exactly where needed.

When do I have to invest how much?

Risk assessments show me what is quality relevant.



Contact Person: Dr.-Ing. Wolfram Kessler

Adress: Hauptplatz 4 6403 Küssnacht, Switzerland

Phone/E-Mail: +41 41 850 96 026 info@reinraum.tech

www.reinraum.tech



Contact Person: Dr. Frank Otto Gombert

Adress: Dornacherstrasse 120 4053 Basel, Switzerland

Phone/E-Mail: +41 76 73 41 489 Frank.Gombert@selmod.com

www.selmod.com www.linkedin.com/company/ selmod/



Contact Person: Dr. Amir Mofidi

Adress: Düsseldorfer Straße 40 65760 Eschborn, Germany

Phone/E-Mail: +49 (0)163 39 35 358 amir_mofidi@sinobiologicaleu.com

www.sinobiological.com

Selmod GmbH

Selective mode antimicrobial resistance therapeutics

Selmod is a startup with a mission dedicated to the development of new antibacterial and antifungal therapies needed to address the critical unmet need for antimicrobial resistance, or AMR for short.

With our first-in-class approach, we perform preclinical research on new targets or new modalities by a new mode of action. Our drug candidates are active against multi-resistant clinical isolates in infection in-vivo studies and are based on new IP-protected chemical modalities.

We offer the opportunity to invest up to 4 million CHF in our 3 preclinical research assets. Investments are done in individual pre-clinical research projects to advance them to the next value-creation milestones. IND ready studies, conclude lead optimization or conclude lead finding.

A Selmod leadership team is a group of highly motivated individuals, focused on developing new therapies for AMR infections, experienced pharma professionals, or expert scientific advisors from Europe and North America. In the last decade, members have contributed to the approval of 2 new antibiotics and 2 investigational antibiotics that have completed phase 3 studies, amongst other clinical candidates in other therapeutic areas.

Sino Biological Europe GmbH

Sino Biological is dedicated to providing the scientific community with highquality recombinant protein and antibody reagents promoting life science research and drug discovery.

With the world's largest validated recombinant protein bank (6500+), Sino offers an extensive selection of antigens including viral proteins, cytokines, growth factors, immune checkpoints, antigens for therapeutic targets, Fc receptors and biomarker proteins. Moreover, Sino Biological has independently developed a comprehensive collection of high-quality monoclonal mouse and rabbit antibodies, including neutralizing antibodies and antibody pairs.

As the specialist in protein recombinant expression and antibody development, Sino Biological is the one-stop shop for robust customized CRO services. In addition, Sino Biological has developed several cutting-edge technologies to accelerate pharmaceutical and pre-clinical antibody drug development, featuring VLPs-based membrane protein expression, nanobody production, Beacon-based single cell sorting antibody development, antibody humanization, anti-idiotypic antibody development and AI-powered antibody affinity maturation.

Sino Biological Europe GmbH is located in Frankfurt with a local sales and service team as well as a comprehensive protein inventory.

Vivacell Biotechnology GmbH

VivaCell Biotechnology GmbH ('VivaCell') is a privately-owned Contract Research Organization (CRO) that provides specialized in vitro and in vivo models for testing and proving the bioactivity, safety, and health benefits of cosmetics, pharmaceutical, nutraceutical, natural and phytopharmaceutical compounds and extracts including but also probiotics. Since its establishment in 1999, the company combines highly qualified cellular and molecular biology knowledge and expertise in a variety of fields and diseases, including cosmetic, dermatology, oral care, metabolic diseases, CNS, menopause syndroms, and many other infications.

VivaCell's preclinical services include a range of established screening assays, as well as protocols and new developed assays specifically adapted to specific customer needs, for screening of products and other indication products including final formulations.

VivaCell offers support in complete research projects. VivaCell's team of experts and skilled scientists provide a solid base of knowledge and expertise in basic R&D and preclinical compound validation. The company developed various screening platforms to screen cosmetic and nutraceutical ingredients rapidly and cheaply (VivaDerma/VivaNutra).



Contact Person: Dr. Bernd Fiebich

Adress: Ferdinand-Porsche Straße 5 79211 Denzlingen, Germany

Phone/E-Mail: +49 (0)179 21 15 187 fiebich@vivacell.de

www.vivacell.de



Contact Person: Dr. Thomas Kuri

Adress: Mülhauser Straße 9 79110 Freiburg, Germany

Phone/E-Mail: +49 (0)761 60 06 87 10 tkuri@zymoresearch.de

www.zymoresearch.de

Zymo Research Europe GmbH

From its birthplace in a small garage in Orange, California, to the industry leader it is today, Zymo Research has been led by a vision to have a positive impact in the biomedical field and to contribute to the greater good of humanity.

Today, Zymo Research is a globally established biotechnology company with international facilities and a global distribution network, that enables researchers in academia and the biomedical field to make cutting-edge discoveries all over the world. Historically recognized as the leader in epigenetics, the company is breaking boundaries with novel solutions for sample collection, microbiomics, and the emerging Next-Gen Sequencing (NGS) technologies - driven by the fundamental belief that "the beauty of science is to make things simple."

Zymo Research Europe (ZRE) in Freiburg serves as distribution hub for Europe, the Middle East, and North Africa, supporting customers with products and scientific advice from scientist to scientist. Equipped with a state-of-theart lab, ZRE also offers NGS services with focus on the field of microbiomics, offering high-end targeted and metagenomic analyses.

Thank you to all sponsors and partners who made this event happen:





 Impressum
 Herausgeber:
 BioValley Deutschland e.V.

 Gestaltung:
 Ulrike Claassens Grafik Design